New EAS Consensus Highlights Advances in Pediatric FH Care
European Atherosclerosis Society shared a post on LinkedIn about a recent article by Albert Wiegman et al., published in European Heart Journal։
“Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) concentrations, which increase the risk of premature atherosclerotic cardiovascular disease (ASCVD).
FH affects around 1 in 300 people worldwide, while the more severe form, Homozygous FH (HoFH), affects about 1 in 300,000 people and can lead to serious cardiovascular complications already in childhood.
Early diagnosis and treatment can dramatically improve – and even normalize – life expectancy.
Yet, fewer than 10% of affected children in Europe are currently identified.
The European Atherosclerosis Society (EAS) consensus statement on FH in children and adolescents highlights:
- Improved diagnostic criteria
- Earlier treatment initiation – sometimes from age 6
- Lower LDL-C treatment targets
- New lipid-lowering therapies
- Updated treatment algorithms
- Better transition from paediatric to adult care.
The statement emphasizes one key message: reducing lifelong exposure to high LDL-C is critical to protecting cardiovascular health from an early age.”
Title: Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement
Authors: Albert Wiegman, Mafalda Bourbon, Tomas Freiberger, Samuel S Gidding, Susanne Greber-Platzer, Urh Groselj, Kirsten B Holven, Lisa C Hudgins, Steve E Humphries, Barbara A Hutten, Daiana Ibarretxe, Cristina Pederiva, Noel Peretti, Frederick J Raal, Uma Ramaswami, Veronika Sanin, Raul D Santos, Elisabeth Steinhagen-Thiessen, Gerald F Watts, Rosie Perkins, Marianne Benn, Christoph J Binder, Stefano Romeo, Jeanine E Roeters van Lennep
Stay updated with Hemostasis Today.
-
May 27, 2026, 13:10Amos Gitonga M: Global Partnerships Supporting Hemophilia and Sickle Cell Care in Africa
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK